Abstract: Provided herein are recombinant polypeptides comprising a SARS-CoV-2 S1 protein binding domain polypeptide and a GM-CSF polypeptide, polynucleotide sequences encoding the same, virus-like particles comprising the same, and methods for using these compositions for the treatment of a SARS-CoV-2 infection in a subject, and for detection of a SARS-CoV-2 antibodies in a subject.

Abstract: Disclosed herein is a method for treating a subject having, or at risk of having, a cancer, comprising administering to the subject a therapeutically effective amount of a tumor membrane vesicle (TMV) and a metformin. In some embodiments, the TMV comprises a B7-1 and/or IL-12 molecule anchored to a lipid membrane (e.g., by a GPI anchor). In some embodiments, the methods can further comprise administering an immune checkpoint inhibitor. The methods are useful for reducing tumor size and metastasis, and in improving anti-tumor immune responses.

Abstract: This disclosure relates to methods of treating cancer using dendritic cells pulsed with tumor membrane vesicles as disclosed herein. In certain embodiments, the tumor membrane vesicles contain fusion proteins with a cytokine and a glycosyl phosphatidylinositol domain. In certain embodiments, the cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF). In certain embodiments, tumor membrane vesicles contain fusion proteins with IL-12 and a glycosyl phosphatidylinositol domain.

Abstract: In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein.

Abstract: In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.

Abstract: Disclosed herein is a method for treating a subject having, or at risk of having, a triple negative breast cancer, comprising administering to the subject a therapeutically effective amount of an immunotherapeutic agent and a tumor membrane vesicle (TMV), wherein the TMV comprises a lipid membrane, and a B7-1 and/or IL-12 molecule anchored to the lipid membrane. Also disclosed is method for predicting the likelihood a human subject having a cancer will respond therapeutically to a TMV immunotherapy, wherein the method comprises obtaining a blood or serum sample from the subject; measuring the amount of a set of biomarkers in the sample, wherein the biomarkers include at least IFN-gamma, TNF-alpha, and IL-2, and wherein an increase in the level of the biomarkers as compared to a control indicates an increased likelihood the subject will respond therapeutically to the TMV immunotherapy.

Abstract: In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein.

Abstract: In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.

Abstract: A therapeutic composition or a vaccine comprising tumor membrane-anchored cytokines or other immunostimulatory or costimulatory molecules are provided. The therapeutic composition or a tumor vaccine can be used for treating a tumor or other disease such as autoimmune disorder, viral diseases, bacterial diseases, parasitic diseases, and transplant rejection.

Abstract: Disclosed are compositions and methods to generate a protective or therapeutic immune response to neoplastic cells (e.g., tumor cells) which, in nature, lack a CoCAM surface molecule essential for a cytotoxic immune response. GPI-anchored CoCAM molecules are incorporated (by GPI-protein transfer) into neoplastic cells, neoplastic cell membrane preparations or neoplastic membrane vesicle preparations and formulated in immunogenic compositions. A specifically exemplified GPI-CoCAM is a B7.1/CD16B fusion protein, having the GPI anchor domain from the CD16B molecule.